ADVA
11.9.2019 09:02:11 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Inoventica has selected its FSP 3000 platform to meet soaring data demand from enterprise and carrier customers. Inoventica, one of Russia’s leading IT service providers and data center operators, will leverage the solution to boost the capacity of its backbone network to 100Gbit/s and beyond. The new fully redundant infrastructure leverages ADVA’s QuadFlex™ line card and OpenFabric™ cross-connect – two technologies optimized for efficiency and complete flexibility. ADVA’s Select partner, the IT solution specialist Zettaline is also playing a key role in facilitating the project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190911005024/en/
“ADVA’s technology enables us to take the next step with our infrastructure while also leveraging maximum value from our existing network. With this deployment, we can flexibly respond to soaring data requirements and help our customers to unleash their full potential,” said Vitaly Slizen, CEO, Inoventica. “The ADVA FSP 3000 delivers several key efficiencies from low latency to optimized bandwidth utilization. And the FSP 3000 OpenFabric™ empowers us to cost-effectively provide the data rates our customers need by aggregating 1Gbit/s and 10Gbit/s services onto 100Gbit/s wavelengths. Furthermore, its openness means we can reap the benefits of unlimited innovation cycles in the future.”
Designed for scalability and bandwidth optimization, the ADVA FSP 3000 ensures that Inoventica’s new infrastructure offers superb efficiency. It enables significant energy savings and, with its 1RU footprint, occupies very little rack space. Using ADVA FSP 3000 QuadFlex™ technology, the solution will transport 100Gbit/s data loads over distances stretching to 2,000km across the Moscow metropolitan area. By enabling greater spectral efficiency, QuadFlex™ delivers extended reach without any need for signal regeneration. Also key is the ADVA FSP 3000 OpenFabric™ , which creates a distributed architecture, enabling Inoventica to simply and efficiently aggregate lower-speed services.
“We’re proud that Russia’s largest cloud service provider has chosen to harness our technology and expertise. Together with our partner Zettaline, we’ve built a solution that efficiently expands Inoventica’s infrastructure and provides the tools it needs to address today’s key challenges,” commented Andreas Jelinek, senior director, sales, Eastern Europe, Russia and CIS, ADVA. “The new fully redundant solution is protected, flexible and extremely cost-efficient. It also meets all of Inoventica’s density, security and energy requirements. Furthermore, thanks to the modular, scalable design of our FSP 3000 platform and the ongoing support of our team, Inoventica is free to plan an exciting roadmap for further development in the future.”
“This deployment is going to bring substantial benefits to a great number of Russian enterprises and we’re proud to be playing such a big part in helping Inoventica take this leap forward. Working closely with our friends at ADVA, we’ve created a transport system that squeezes maximum value from Inoventica’s existing resources while enabling the flexibility and capacity necessary for the 5G and IoT era,” said Alexander Hochmuth, shareholder representative, Zettaline Ltd. “As a team, ADVA and Zettaline provide both global knowledge and local expertise. Together, we’ve designed an open, disaggregated and completely future-proof solution that meets all of Inoventica’s needs and ambitions.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com .
About Inoventica
INOVENTICA Group of Companies is the first Russian IT-operator that has been implementing projects based on innovative ICT Infrastructure of international scale based on cloud computing technologies since 1999. Partners and clients of the INOVENTICA Group of Companies are more than 5 thousand B2C subscribers, more than 1000 corporate clients (B2B), 48 national and international telecom operators. www.invs.ru
Published by:
ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190911005024/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
